Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PharmaEngine, Inc. (4162.TWO)
Taipei, TW
PharmaEngine, Inc. is a biopharmaceutical firm specializing in the creation and advancement of oncology therapeutics, primarily targeting markets in Taiwan and Europe. Its leading drug candidate is ONIVYDE, an innovative liposomal formulation of irinotecan. This topoisomerase 1 inhibitor is designed to treat metastatic pancreatic cancer. The company's pipeline also includes PEP06, currently in Phase I clinical trials for various cancers, and PEP07. PEP07, a Chk1 inhibitor in preclinical development, is being investigated for its ability to induce DNA damage and programmed cell death (apoptosis), leading to "replication catastrophe" in cancer cells. Established in 2002, PharmaEngine, Inc. maintains its corporate headquarters in Taipei, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.45% | -5.90% | -7.98% | -18.86% | -23.77% | -23.01% | -40.70% | -42.71% | -8.91% | -66.86% | -10.09% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-02 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-63.9% Q1'26: +28.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-77.9% Q1'26: +33.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+210.6% ★ Q1'26: +108.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+46.7% ★ Q1'26: +54.2% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+128.9% ★ Q1'26: +326.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'26: -0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.10× ★ Q1'26: 0.08× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
507.24M
est: 627.67M (-19.2%)
|
1.13B
est: 1.14B (-0.6%)
|
853.68M
est: 889.23M (-4.0%)
|
293.43M
est: 289.60M (+1.3%)
|
314.04M
est: 330.00M (-4.8%)
|
1.06B
est: 383.50M (+175.4%)
|
654.84M
est: 651.00M (+0.6%)
|
654.38M
est: 656.00M (-0.2%)
|
767.67M
est: 859.64M (-10.7%)
|
2.52B
est: 2.45B (+3.2%)
|
911.42M
est: 910.00M (+0.2%)
|
1.03B
1.03B – 1.03B
+13.1% YoY
|
2.94B
2.94B – 2.94B
+185.8% YoY
|
| EBITDA |
328.96M
est: 439.39M (-25.1%)
|
811.12M
est: 799.19M (+1.5%)
|
616.02M
est: 622.49M (-1.0%)
|
166.70M
est: 202.73M (-17.8%)
|
56.49M
est: 231.01M (-75.5%)
|
765.48M
est: 268.46M (+185.1%)
|
555.87M
est: 455.72M (+22.0%)
|
401.15M
est: 459.22M (-12.6%)
|
347.31M
est: 559.30M (-37.9%)
|
2.17B
est: 1.59B (+36.6%)
|
435.51M
est: 592.07M (-26.4%)
|
669.49M
669.49M – 669.49M
+13.1% YoY
|
1.91B
1.91B – 1.91B
+185.8% YoY
|
| EBIT |
327.33M
est: 432.34M (-24.3%)
|
808.12M
est: 786.37M (+2.8%)
|
612.97M
est: 612.50M (+0.1%)
|
163.77M
est: 199.48M (-17.9%)
|
49.78M
est: 227.30M (-78.1%)
|
752.92M
est: 264.15M (+185.0%)
|
545.61M
est: 448.41M (+21.7%)
|
392.54M
est: 451.85M (-13.1%)
|
338.28M
est: 549.79M (-38.5%)
|
2.16B
est: 1.56B (+38.3%)
|
425.46M
est: 582.00M (-26.9%)
|
658.11M
658.11M – 658.11M
+13.1% YoY
|
1.88B
1.88B – 1.88B
+185.8% YoY
|
| Net Income |
394.02M
est: 461.00M (-14.5%)
|
689.63M
est: 627.84M (+9.8%)
|
387.06M
est: 442.75M (-12.6%)
|
129.36M
est: 82.58M (+56.6%)
|
42.55M
est: 86.36M (-50.7%)
|
604.28M
est: 95.79M (+530.8%)
|
426.03M
est: 307.88M (+38.4%)
|
318.78M
est: 286.41M (+11.3%)
|
274.65M
est: 359.54M (-23.6%)
|
1.75B
est: 1.74B (+0.5%)
|
387.64M
est: 388.64M (-0.3%)
|
505.23M
505.23M – 505.23M
+30.0% YoY
|
2.01B
2.01B – 2.01B
+296.9% YoY
|
| SGA |
58.34M
est: 92.27M (-36.8%)
|
129.90M
est: 167.84M (-22.6%)
|
115.97M
est: 130.73M (-11.3%)
|
113.23M
est: 42.57M (+166.0%)
|
118.84M
est: 48.51M (+145.0%)
|
113.35M
est: 56.38M (+101.0%)
|
118.40M
est: 95.70M (+23.7%)
|
140.06M
est: 96.44M (+45.2%)
|
131.51M
est: 131.38M (+0.1%)
|
155.37M
est: 373.66M (-58.4%)
|
124.33M
est: 139.07M (-10.6%)
|
157.26M
157.26M – 157.26M
+13.1% YoY
|
449.47M
449.47M – 449.47M
+185.8% YoY
|
| EPS |
2.69
est: 3.20 (-16.0%)
|
4.71
est: 4.36 (+8.0%)
|
2.63
est: 3.08 (-14.5%)
|
0.88
est: 0.57 (+53.4%)
|
0.29
est: 0.60 (-51.7%)
|
4.15
est: 0.67 (+523.5%)
|
2.95
est: 2.14 (+37.9%)
|
2.22
est: 1.99 (+11.6%)
|
1.91
est: 2.50 (-23.5%)
|
12.16
est: 12.11 (+0.5%)
|
2.70
est: 2.70 (+0.0%)
|
3.51
3.51 – 3.51
+30.0% YoY
|
13.93
13.93 – 13.93
+296.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.02% | 20.2K | 0.42% |
| 2 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.00% | 18.1K | 0.33% |
| 3 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 83.1K | 0.46% |
| 4 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 576.6K | 0.06% |
| 5 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 22.3K | 0.44% |
| 6 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 245.3K | 0.39% |
| 7 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 200.4K | 0.29% |
| 8 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.00% | 3.9K | 0.35% |
| 9 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 153.5K | 0.28% |
| 10 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 17.8K | 0.48% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chi-Hsing Chang | Vice President of Corporate Development | 4M | male |
| Hong-Ren Wang | President & Chief Executive Officer | — | male |
| Melody Lin | Director of Human Resources | — | — |
| Yu Gen Cao | Accounting Supervisor | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4162.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
